安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Terran Biosciences
Our portfolio includes a late-stage therapy for schizophrenia, late-stage selective serotonin 2A receptor antagonists, a drug design engine that has enabled first-in-class and best-in-class psychedelic therapies, and an AI-enabled imaging software platform
- TerXT by Terran Biosciences
The combination of xanomeline and trospium has been shown in clinical trials to be an effective treatment for schizophrenia Designed for once-daily oral dosing to improve ease of use
- TerXT: Combination of Xanomeline and Trospium Prodrugs for Schizophrenia
Terran Biosciences announces development of TerXT, a combination of xanomeline and trospium prodrugs for the treatment of schizophrenia, and intends to pursue accelerated 505(b)(2) approval pathway News release
- Terran Biosciences Announces Development of TerXT, a Combination of . . .
To develop TerXT, Terran sought to overcome inherent pharmacokinetic and physical property limitations of the compounds xanomeline and trospium, such as poor colonic absorption and high aqueous solubility, by utilizing a novel prodrug strategy
- Terran Biosciences Announces Development of TerXT, a . . . - BioSpace
Terran Biosciences Inc has announced the development of TerXT, a combination of novel prodrugs of xanomeline and trospium designed to be long-acting treatments for schizophrenia
- Terran Biosciences Unveils Remarkable Breakthrough: TERXT for Schizophrenia
Terran Biosciences has developed TerXT, a combination of novel prodrugs of xanomeline and trospium, for treating schizophrenia The prodrug approach aims to overcome the limitations of xanomeline and trospium, enabling fixed-dose combinations for once-daily oral administration and long-acting intramuscular injections
- Terran Biosciences prepares for trials of schizophrenia drug
Terran Biosciences is aiming to launch two Phase I trials of its candidate TerXT for patients with schizophrenia Terran Biosciences CEO Sam Clark told the Clinical Trials Arena that TerXT is a long-acting pro-drug of Bristol Myers Squibb’s (BMS) KarXT, a combination of xanomeline and trospium
- Interview with Terran’s CEO Sam Clark - Schizophrenia. com
Terran Biosciences Announces Development of TerXT, a Combination of Xanomeline and Trospium Prodrugs for the Treatment of Schizophrenia, and Intends to Pursue Accelerated 505(b)(2) Approval Pathway
|
|
|